Several studies have confirmed a preclinical activity for the most-studied PARP inhibitors (PARPi)—olaparib, niraparib, and talazoparib—in combination with cytotoxic, hypomethylating, and histone deacetylase inhibitors or targeted drugs in AML [10,11,12,13]. The gene discussed is PARP1; the disease is acute myeloid leukemia.